• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes

    9/22/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email

    MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the high-throughput carrier screening market with a significantly expanded and enhanced suite of PureTarget products. The updated solutions leverage PacBio's highly accurate HiFi sequencing technology to allow clinical laboratories to consolidate multiple specialized assays into a single, scalable test capable of resolving some of the most challenging genes associated with inherited conditions.

    Recent research shows that up to 71% of individuals carry at least one pathogenic variant, highlighting the growing importance of carrier screening in family planning.¹ The use of carrier screening is rapidly expanding across commercial labs, health systems, and government-funded programs worldwide. The analysis of technically difficult hereditary genes – such as those linked to fragile X syndrome (FMR1), spinal muscular atrophy (SMN1), and Friedreich Ataxia (FXN) – has historically required multiple technologies and specialized workflows. This fragmentation slowed adoption of comprehensive carrier screening, increased costs, and limited global access.

    PacBio's expanded PureTarget portfolio now provides laboratories with broad, accurate carrier screening solutions, including coverage of all challenging tier 3 genes identified in the American College of Medical Genetics technical standard.² The panels are available in 24- and 96-sample kit formats, with three complementary configurations designed to meet a range of laboratory needs:

    • A carrier screening panel for inherited reproductive conditions
    • A repeat expansion disorder panel for neurological diseases
    • A control panel to support custom assay design and validation

    Together, these kits allow laboratories to replace multiple specialized assays with a single streamlined workflow, adaptable from targeted clinical programs to national population-screening initiatives.

    "PureTarget is a breakthrough because it focuses PacBio's outstanding long-read sequencing quality on clinically relevant, hard-to-sequence regions across many samples at once," said Dale Muzzey, Chief Scientific Officer of Myriad Genomics. "This approach not only streamlines lab workflows by reducing the need for multiple specialized assays, but it can also enhance both the sensitivity and specificity of results. It's a win for labs, clinicians, and patients."

    The upgraded kits support throughput of up to 100,000 samples per year on a single Revio system, making them ideal for population-scale screening initiatives, reproductive health clinics, and large health systems.

    "Clinical laboratories need scalable, accurate, and easy-to-use carrier screening tools," said Christian Henry, President and Chief Executive Officer of PacBio. "Our carrier screening products consolidate fragmented workflows into one test, enabling laboratories everywhere to offer comprehensive carrier screening at scale, with high confidence in clinical outcomes and operational efficiency. All of this is possible at price points required to enable laboratories to make a profit given the reimbursement rates available for this type of testing."

    With the addition of a carrier screening panel, expanded disease gene content, automation support, and custom panel design, PureTarget gives laboratories the flexibility to scale programs securely and efficiently. PacBio's entry into this market shows a clear commitment to simplifying complex genomic testing and expanding access to comprehensive screening worldwide.

    For more information, visit: https://www.pacb.com/technology/puretarget.

    Notes

    ¹ Guo, D., et al. (2025). Regional patterns of genetic variants in expanded carrier screening. Frontiers in Genetics. https://doi.org/10.3389/fgene.2025.1527228

    ² Guha, S., Aarabi, M., DiStefano, M., Wakeling, E., et al. (2024). Laboratory testing for preconception/prenatal carrier screening: ACMG technical standard. Genetics in Medicine. https://doi.org/10.1016/j.gim.2024.101137

    About PacBio 

    PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio. 

    PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. 

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, or the benefits or expected benefits of using, PacBio products or technologies, including in connection with PureTarget, consolidating multiple assays into a single broad and accurate panel assay, streamlined workflows, interrogating difficult genes, operational efficiency, throughput, scalability, customization, automation, accuracy, ease of use, potential use cases, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in tariffs, costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; diagnostic product promotion regulations; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements, including PacBio's preliminary unaudited financial information and PacBio's financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

    Contacts 

    Investors:

    Todd Friedman 

    [email protected] 

    Media:

    [email protected] 



    Primary Logo

    Get the next $PACB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/17/2023$13.00 → $10.00Neutral → Buy
    UBS
    More analyst ratings

    $PACB
    SEC Filings

    View All

    SEC Form S-8 filed by Pacific Biosciences of California Inc.

    S-8 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    8/7/25 4:51:37 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Pacific Biosciences of California Inc.

    10-Q - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    8/7/25 4:38:41 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    8/7/25 4:12:59 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes

    MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the high-throughput carrier screening market with a significantly expanded and enhanced suite of PureTarget products. The updated solutions leverage PacBio's highly accurate HiFi sequencing technology to allow clinical laboratories to consolidate multiple specialized assays into a single, scalable test capable of resolving some of the most challenging genes associated with inherited conditions. Recent research shows that up to 71% of individuals carry at least one pathogenic variant, highlighting the growing

    9/22/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow

    MENLO PARK, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The partnership brings EpiCypher's CUTANA® Hia5 enzyme to market for use with Fiber-seq assays on PacBio HiFi sequencing systems, giving researchers a new way to see chromatin biology at single-molecule resolution. Fiber-seq (single-molecule chromatin fiber sequencing) is an advanced multi-omic whole genome sequencing (WGS) assay that simultaneously measures chromatin accessibility, DNA methylation, and DNA variation on ind

    9/3/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces Second Quarter 2025 Financial Results

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspo

    8/7/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pacific Biosciences downgraded by UBS

    UBS downgraded Pacific Biosciences from Buy to Neutral

    11/11/24 9:44:33 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Pacific Biosciences with a new price target

    Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

    6/3/24 8:16:36 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences downgraded by JP Morgan

    JP Morgan downgraded Pacific Biosciences from Overweight to Neutral

    4/22/24 7:40:44 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Van Oene Mark sold $35,182 worth of shares (26,836 units at $1.31), decreasing direct ownership by 1% to 1,920,035 units (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    8/20/25 4:06:46 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Mohr Marshall

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    6/6/25 4:10:59 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Livingston Randall S

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    6/6/25 4:10:13 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/6/24 5:36:07 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Financials

    Live finance-specific insights

    View All

    PacBio Announces Second Quarter 2025 Financial Results

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspo

    8/7/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025

    MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, August 7, 2025, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q2

    7/21/25 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces First Quarter 2025 Financial Results

    MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

    5/8/25 4:15:34 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

    MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

    5/22/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jim Gibson to join PacBio as Chief Financial Officer

    MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

    3/27/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

    MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

    2/3/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

    SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:48:11 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials